Shareholders, analysts, the media and other interested parties can find relevant information for assessing the company here.
15 years of continuous innovation in internal fixation
All necessary financial information of the company at a glance.
All press releases and ad-hoc releases from Medartis.
Sales in CHFm
7% growth in CHF
10% growth in local currencies
EBITDA in CHFm
16% EBITDA margin
15% adj. EBITDA margin(1)
- Good sales growth above the market
- 10% sales growth in local currencies
- Adj. EBIT at 5%(1) of sales
- 48 new jobs added over 12 months
(1) Excluding a provision for possible price and commission agreements in Brazil of CHF 3.0 million and excluding the release of pension fund provisions of CHF 3.4 million.
|Operating profit (EBIT)||6.1||9.3(1)||7.4||7.0(4)||-25%|
(1) Excluding capital market-related costs (IPO) of CHF 3.2 million.
(2) Excluding positive effect from pension fund plan amendment of CHF 0.7 million.
(3) Excluding a provision for possible price and commission agreements in Brazil of CHF 3.0 million and excluding positive effect from pension fund plan amendment of CHF 2.7 million.
(4) Excluding a provision for possible price and commission agreements in Brazil of CHF 3.0 million and excluding positive effect from pension fund plan amendment of CHF 3.4 million.
(5) Year-end figure as per 31.12.2019.
Medartis relies on efficient cooperation between the Board of Directors and the company management. We respect the interests of our shareholders and rely on clear rules in addition to open, transparent corporate communication.
|NAME||POSITION||COMMITTEE MEMBERSHIP||FIRST ELECTED||END CURRENT PERIOD|
|Dr. h.c. Thomas Straumann||Chairman||-||1998||2021||add|
|Dominik Ellenrieder||Vice Chairman||Chairman of the RC|
Member of the SIC
|Willi Miesch||Member of the Board||Chairman of the SIC|
Member of the RC
|Dr. Jürg Greuter||Member of the Board||Member of the RC||1997||2021||add|
|Dr. med. Daniel B. Herren||Member of the Board||Member of the SIC||2017||2021||add|
|Roland Hess||Member of the Board||Chairman of the FAC||2017||2021||add|
|Damien Tappy||Member of the Board||Member of the FAC||2018||2021||add|
|Marco Gadola||Member of the Board||Member of the FAC||2020||2021||add|
RC = Remuneration Committee | FAC = Finance and Audit Committee | SIC = Strategy and Innovation Committee
Publication of 2020 half-year results
Publication of 2020 full-year results
The following analysts evaluate the performance of Medartis stock and the investment opportunities for investors.
Ms Sibylle Bischofberger
Bryan Garnier & Co.
Mr Hugo Solvet
26 Avenue des Champs-Elysées
Mr Arsène Guekam, Ms Maja Pataki
Route de Crassier 11
Frau Tanya Hansalik
Would you like to be informed about Medartis at first hand? Register and receive our news in electronic form.